An­oth­er busy week for IPOs be­gins with an off-the shelf cell ther­a­py play­er sniff­ing around uni­corn sta­tus

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

A flur­ry of biotechs are ex­pect­ed to hit Nas­daq this week, with two com­pa­nies, Am­brx Bio­phar­ma and Cen­tu­ry Ther­a­peu­tics, set­ting the terms for their pub­lic de­buts, with ex­pect­ed rais­es at $126 mil­lion and $200 mil­lion, re­spec­tive­ly. Alza­mend Neu­ro is al­so join­ing in with a $12.5 mil­lion raise and two pre­clin­i­cal Alzheimer’s treat­ments in tow.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.